Rothschild & Co Redburn analyst Jamie Clark lowered the firm’s price target on Iqvia (IQV) to $214 from $228 and keeps a Buy rating on the shares. The firm says the company offers the lowest risk in the life science group with its contract research organization business having shown more resilience than peer Icon’s over the past 12 months and its technology and analytics segment providing diversification.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV: